ArticleDermatology and therapy2025
Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03732807 (A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A phase 2b/3 randomized, double-blind, placebo-controlled, dose-ranging study to investigate the efficacy and safety of pf-06651600 in adult and adolescent alopecia areata (aa) subjects with 50% or greater scalp hair loss
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe ALLEGRO- 2b/3 (Clinicaltrials.gov Identifier: NCT03732807) study demonstrated efficacy and safety of ritlecitinib in patients with alopecia areata (AA). Despite clinically meaningful improvement in hair regrowth, differences in patient-reported emotional symptoms or activity limitations (subscales of the Alopecia Areata Patient Priority Outcomes [AAPPO]) between treatment groups were not significant. This study aimed to identify potential factors that may impact the measurement of patient-reported outcomes in AA.
methodsThis mixed methods study conducted remote interviews with individuals with self-reported AA. Interviews were designed to understand how experiences with AA impacted study participant health-related quality of life and gain insights into how historical personal circumstances and individual characteristics might impact AAPPO responses. Qualitative data were analyzed using thematic and content analytical processes; quantitative data were analyzed descriptively.
resultsQualitative analysis of interview transcripts of 30 adults with AA (seeking or had received AA treatment) yielded three overarching themes: mechanisms of adaptation (subthemes: behavioral and mental strategies), impact changes over disease journey (subthemes: hair loss and regrowth as an event and changes in impact over time after loss and/or regrowth), and underlying characteristics that moderate adaptation. Participants reported requiring 50-100% regrowth for 6-12 months before they would provide different AAPPO emotional and activity limitation responses.
conclusionsHigh levels of hair regrowth over a sustained period of time would be required to change AAPPO responses. Factors identified that may affect measurement of patient-reported psychosocial outcomes in AA included length of time since hair regrowth. Understanding factors that impact adaptation can help inform clinical practice and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.